The advent of high-sensitivity troponin assays to enable the quantification of troponin concentration in up to 95% of the general population is thought to improve clinical care in patients presenting with suspected infarction.
1, 2 The application of high-sensitivity troponin assays could be beneficial by enabling the early ruling out of myocardial infarction on the basis of very low troponin concentrations;
3-7 precise and rapid diagnosis of myocardial infarction on the basis of troponin-based algorithms 8, 9 followed by early treatment initiation; and improved risk stratification on the basis of low troponin concentrations that are only detectable by highsensitivity assays.
1
In The Lancet, the High-STEACS Investigators 10 present an innovative and impressive strategy to compare a truly high-sensitivity troponin assay with previous contemporary troponin testing by use of a clusterrandomised controlled trial design. This design allows the comparison of outcomes 1 year after patient presentation at the emergency department, before and after implementation of this high-sensitivity assay across ten hospitals in Scotland.
The trial is large, with almost 50 000 patients included. Among the study population, 10 360 (21%) patients had troponin concentrations greater than those of the 99th percentile. Notably, 1771 (17%) of these 10 360 patients were reclassified by the highsensitivity strategy, resulting in additional patients who had not been identified by the contemporary assay being identified by the high-sensitivity assay. These patients would have been missed if we were only to use the conventional assay.
How did this high-sensitivity approach affect cardiovascular outcomes, and what was the net benefit of identifying these reclassified patients? Within 1 year, 2586 (5%) patients had a subsequent myocardial infarction or death from cardiovascular causes, and these outcomes were more common in patients who had been reclassified. However, use of a high-sensitivity assay to diagnose those at risk did not significantly affect the risk of the combined endpoint of subsequent myocardial infarction or cardiovascular death (which occurred in 15% of reclassified patients during the validation phase vs 12% of these patients during the implementation phase). Therefore, Anoop Shah and colleagues 10 report no benefit to the high-sensitivity strategy investigated.
This nationwide approach represents an intelligent approach to make clinical routine data accessible within the frame of a clinical trial. However, there still might be some crucial points to consider. It is a self-fulfilling conundrum that application of a high-sensitivity assay leads to a higher number of diagnoses of myocardial infarction when lower thresholds are applied. Ideally, earlier and more sensitive detection of myocardial infarction should lead to better therapeutic strategies and should also translate into better outcome. Obviously, this result is not observed in Scotland during and after the implementation phase. The application of high-sensitivity assays is not associated with a difference in outcome at 1 year in the study by Shah and colleagues. This finding might be explained by various factors. First, strong evidence proves the association between troponin concentration and outcome in disease-based and population-based studies, even at low concentrations. This association becomes stronger over time and is most likely not apparent after 1 year. A follow-up of 1 year is not sufficient to determine the benefit of clinical decision making that is based on more sensitive troponin assays. Second, although the use of coronary angiographies in reclassified patients was more common, the number of patients that received percutaneous coronary intervention was unchanged. Medical therapy was moderately improved in the reclassified patients, but the absolute numbers were small (new single or double antiplatelet drugs were used in 171 patients and new statins in 47 patients). These slight changes in medical treatment do not affect outcome after 1 year. Finally, and most importantly, the adoption of the 99th percentile as a threshold for the high-sensitivity assays largely ignores their potential. The 99th percentile of the high-sensitivity troponin assay is almost completely recognisable by the contemporary sensitive test (only 17% of those identified by which were reclassified). Hence, the use of the high-sensitivity assays in the implementation phase did not take advantage of the highly sensitive nature of the test.
Although this trial focused on the effects of highsensitivity troponin assays for diagnosing myocardial infarction and progresses our understanding, additional
